Viriom Inc
Innovative Treatments for HIV and Chronic HBV Infections Worldwide
Innovative Treatments for HIV and Chronic HBV Infections Worldwide
Viriom Inc. is a biotech firm founded in 2009 with a focus on developing innovative and affordable medications for life-threatening infections such as HIV and HBV. The company holds an exclusive global license from Hoffmann-La Roche and its lead compounds - Elpida/elsulfavirine and VM1500A - are in advanced phases. In addition, Viriom has proprietary drug candidates VM2500 and VM3500 LAI formulations, as well as combinations involving cell, vaccine, and antibody drugs aimed at treating, preventing, and curing HIV and chronic HBV infections worldwide. The last investment round, a $12.50M Convertible Note investment from Pharmstandard, took place on 06 December 2017. The company operates within the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $12.50M | 1 | Pharmstandard | 06 Dec 2017 |
| Convertible Note | $2.56M | 1 |
|
06 Jun 2017 |
| Convertible Note | $2.35M | 3 |
|
11 May 2016 |
| Convertible Note | $3.00M | 1 |
|
01 Sep 2015 |
| Seed Round | $5.00M | 2 | MIT RF, ChemRar Ventures | 01 Dec 2012 |
No recent news or press coverage available for Viriom Inc.
We care about your data, and we'd love to use cookies make your experience better.
